Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Ying C., Liu, Lucy, Tariq, Bilal, Wang, Kun, Jindal, Ashutosh, Tang, Zhiyu, Gao, Yuying, Sahasranaman, Srikumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993273/
https://www.ncbi.nlm.nih.gov/pubmed/33306268
http://dx.doi.org/10.1111/cts.12948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993273/
https://www.ncbi.nlm.nih.gov/pubmed/33306268
http://dx.doi.org/10.1111/cts.12948

Ejemplares similares